3081
T3D3039
Hexobarbital
Hexobarbital is only found in individuals that have used or taken this drug. It is a barbiturate that is effective as a hypnotic and sedative. [PubChem]Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
56-29-1
3608
C12H16N2O3
236.116090
White powder.
146.5°C
435 mg/L (at 25°C)
Oral
Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Hepatic.
No indication of carcinogenicity to humans (not listed by IARC).
For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
2009-07-21T20:28:47Z
2014-12-24T20:25:56Z
Hexobarbital
C11723
5706
Hexobarbital
DB01355
true
CN1C(=O)N=C(O)C(C)(C2=CCCCC2)C1=O
C12H16N2O3
InChI=1/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
InChIKey=UYXAWHWODHRRMR-UHFFFAOYNA-N
236.267
236.116092388
Exogenous
Solid
1.98
HMDB15444
CHEMBL7728
3482